Log In

Forgot Password?

OR

Not a member? Continue as a nonmember.

Become a Member

By becoming a member of the AAN, you can receive exclusive information to help you at every stage of your career. Benefits include:

Join Now See All Benefits

Loading... please wait

Abstract Details

Patient Characteristics and Persistence Among Commercially Insured Patients With Multiple Sclerosis Initiating Cladribine Tablets
Multiple Sclerosis
P14 - Poster Session 14 (11:45 AM-12:45 PM)
3-001
Real-world evidence for CladT in patients with MS is emerging.
To evaluate patient characteristics and 1-year treatment persistence among patients with multiple sclerosis (MS) initiating cladribine tablets (CladT).
Patients with ≥1 CladT claim (4/1/2019–12/31/2020; first CladT claim=index date), ≥2 MS diagnoses ≥30 days apart (1/1/2012–12/31/2021), continuous insurance 1 year before (baseline period) and after (follow-up period) the month of the index date, and age 18–64 from the IQVIA PharMetrics® Plus database were included. Patient characteristics evaluated were age, sex, geographic region, Charlson Comorbidity Index (CCI) score, select comorbidities, and prior disease-modifying therapies (DMTs). Patients were considered persistent if they had 2 CladT claims during follow-up without ≥1 non-CladT DMT claim (ie, switch).
Among 830 patients with ≥1 CladT claim, 200 met inclusion criteria (mean [SD] age 45.3 [10.0] years; 76.0% female; 40.5% South, 28% Midwest, 23.5% Northeast, 7.5% West). Mean (SD) CCI score was 0.54 (1.02). Top comorbidities included depression/anxiety (41.0%), mild liver disease (8.5%), and chronic lung disease (9.5%). A non-CladT DMT claim was present in 66.5% of patients during the baseline period. Of those on DMTs in the 1-year baseline period, patients switched from dimethyl fumarate (10.5%), fingolimod (10.5%), natalizumab (10.5%), ocrelizumab (10.5%), teriflunomide (8%), glatiramer acetate (7.5%), and subcutaneous interferon beta-1a (5.5%). Of the 200 patients, 189 (94.5%) had 2 claims for CladT during follow-up, and of these, 3 switched to another DMT. Of the 11 (5.5%) who had only 1 CladT claim during follow-up, 4 switched to another DMT. Overall, 7 (3.5%) switched to other DMTs (siponimod, dimethyl fumarate, glatiramer acetate, and ocrelizumab). Overall persistence was 93.0%, and mean (SE) survival time until first evidence of nonpersistence was 215.2 (3.2) days.

In the 1 year after CladT initiation, nearly all patients completed their first CladT treatment cycle, and few switched to another DMT.

 

Authors/Disclosures
Chris M. Kozma
PRESENTER
No disclosure on file
Emily L. Evans, MD Dr. Evans has received personal compensation for serving as an employee of EMD Serono. Dr. Evans has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genentech. Dr. Evans has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biogen. Dr. Evans has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genzyme. Dr. Evans has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for EMD Serono. Dr. Evans has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Biogen. Dr. Evans has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Genzyme. Dr. Evans has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Novartis.
Lori Lebson Lori Lebson has nothing to disclose.
Amy L. Phillips, PharmD (EMD Serono) Amy L. Phillips, PharmD has received personal compensation for serving as an employee of EMD Serono, Inc.
Carroline Lobo, PhD (EMD Serono Inc. - Rockland, MA) Carroline Lobo has received personal compensation for serving as an employee of EMD Serono.